恒瑞医药(600276.SH)：HRS-7172片获得药物临床试验批准通知书

Group 1 - The core point of the article is that Heng Rui Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of HRS-7172 tablets, a new type of small molecule inhibitor for cancer treatment developed by the company [1] Group 2 - HRS-7172 tablets are positioned as a novel anti-tumor drug, indicating the company's focus on innovative oncology therapies [1]